+

SI2885288T1 - Analogi 1,4-disubstituiranega piridazina in postopki zdravljenja stanj povezanih s pomanjkanjem SMN - Google Patents

Analogi 1,4-disubstituiranega piridazina in postopki zdravljenja stanj povezanih s pomanjkanjem SMN

Info

Publication number
SI2885288T1
SI2885288T1 SI201331954T SI201331954T SI2885288T1 SI 2885288 T1 SI2885288 T1 SI 2885288T1 SI 201331954 T SI201331954 T SI 201331954T SI 201331954 T SI201331954 T SI 201331954T SI 2885288 T1 SI2885288 T1 SI 2885288T1
Authority
SI
Slovenia
Prior art keywords
deficiency
methods
related conditions
disubstituted pyridazine
smn
Prior art date
Application number
SI201331954T
Other languages
English (en)
Inventor
Atwood Cheung
Donovan Noel Chin
Natalie Dales
Aleem Fazal
Timothy Brian Hurley
John Kerrigan
Gary O'brien
Lei Shu
Robert Sun
Moo Sung
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49029227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2885288(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI2885288T1 publication Critical patent/SI2885288T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI201331954T 2012-08-13 2013-08-13 Analogi 1,4-disubstituiranega piridazina in postopki zdravljenja stanj povezanih s pomanjkanjem SMN SI2885288T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261682448P 2012-08-13 2012-08-13
EP13752768.5A EP2885288B1 (en) 2012-08-13 2013-08-13 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
PCT/US2013/054687 WO2014028459A1 (en) 2012-08-13 2013-08-13 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions

Publications (1)

Publication Number Publication Date
SI2885288T1 true SI2885288T1 (sl) 2022-01-31

Family

ID=49029227

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331954T SI2885288T1 (sl) 2012-08-13 2013-08-13 Analogi 1,4-disubstituiranega piridazina in postopki zdravljenja stanj povezanih s pomanjkanjem SMN

Country Status (41)

Country Link
US (6) US8729263B2 (sl)
EP (3) EP2885288B1 (sl)
JP (1) JP6190883B2 (sl)
KR (3) KR102368439B1 (sl)
CN (1) CN104583196B (sl)
AP (1) AP2015008242A0 (sl)
AR (1) AR092108A1 (sl)
BR (1) BR112015003004B1 (sl)
CA (1) CA2880273A1 (sl)
CL (1) CL2015000331A1 (sl)
CR (1) CR20150078A (sl)
CU (1) CU20150014A7 (sl)
CY (1) CY1124882T1 (sl)
DK (1) DK2885288T3 (sl)
EA (1) EA032005B1 (sl)
EC (1) ECSP15009862A (sl)
ES (2) ES2950450T3 (sl)
GT (1) GT201500030A (sl)
HK (1) HK1207862A1 (sl)
HR (1) HRP20211957T1 (sl)
HU (1) HUE057007T2 (sl)
IL (1) IL237067B (sl)
JO (1) JO3530B1 (sl)
LT (1) LT2885288T (sl)
MA (1) MA37834A1 (sl)
MX (2) MX375731B (sl)
MY (2) MY176488A (sl)
NZ (1) NZ704738A (sl)
PE (2) PE20201165A1 (sl)
PH (1) PH12015500236B1 (sl)
PL (1) PL2885288T3 (sl)
PT (1) PT2885288T (sl)
RS (1) RS62692B1 (sl)
SG (2) SG11201500507UA (sl)
SI (1) SI2885288T1 (sl)
TN (1) TN2015000038A1 (sl)
TW (1) TWI635083B (sl)
UA (1) UA114726C2 (sl)
UY (1) UY34974A (sl)
WO (1) WO2014028459A1 (sl)
ZA (1) ZA201500531B (sl)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403815B2 (en) 2010-06-24 2016-08-02 The Regents Of The University Of California Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
US8729263B2 (en) * 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
US9938263B2 (en) 2013-03-12 2018-04-10 The General Hospital Corporation Gamma-secretase modulators
US20160184305A1 (en) * 2013-07-31 2016-06-30 Novartis Ag 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating smn-deficiency-related conditions
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
CN107109411B (zh) 2014-10-03 2022-07-01 冷泉港实验室 核基因输出的定向增加
CA2966423C (en) * 2014-10-31 2023-10-24 The General Hospital Corporation Potent gamma-secretase modulators
EP3053577A1 (en) 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
JP6884102B2 (ja) * 2015-02-09 2021-06-09 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための化合物
SG11201802870RA (en) 2015-10-09 2018-05-30 Univ Southampton Modulation of gene expression and screening for deregulated protein expression
KR20220100719A (ko) * 2015-12-10 2022-07-15 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
CA3005256A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
JP2019511562A (ja) * 2016-02-01 2019-04-25 アラーキス セラピューティクス， インコーポレイテッド Ｒｎａ媒介疾患を処置する化合物および方法
CA3015345A1 (en) 2016-02-23 2017-08-31 Indiana University Research & Technology Corporation Combination therapies for treatment of spinal muscular atrophy
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
KR20200017476A (ko) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
CN111182898B (zh) 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
IL273741B (en) 2017-08-04 2022-09-01 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
CN114645048A (zh) 2017-08-25 2022-06-21 斯托克制药公司 用于治疗病况和疾病的反义寡聚体
GB2584204B (en) 2017-10-23 2023-06-28 Stoke Therapeutics Inc Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases
CA3085366A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
KR20200142039A (ko) * 2018-04-10 2020-12-21 스카이호크 테라퓨틱스, 인코포레이티드 암 치료용 화합물
EP3788169A4 (en) 2018-05-04 2022-08-10 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
AU2019294482B2 (en) 2018-06-27 2022-09-01 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
ES2983003T3 (es) 2018-06-27 2024-10-21 Ptc Therapeutics Inc Compuestos heterocíclicos y heteroarílicos para el tratamiento de la enfermedad de Huntington
WO2020051282A1 (en) 2018-09-07 2020-03-12 Teva Pharmaceuticals International Gmbh Solid state forms of branaplam and their preparation
KR20210107038A (ko) * 2018-12-21 2021-08-31 노파르티스 아게 브라나플람의 경구 제형
EP3920918A4 (en) * 2019-02-05 2022-11-16 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
CN118812532A (zh) * 2019-02-05 2024-10-22 斯基霍克疗法公司 用于调节剪接的方法和组合物
KR20210123344A (ko) * 2019-02-05 2021-10-13 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
CN113677344A (zh) * 2019-02-06 2021-11-19 斯基霍克疗法公司 用于调节剪接的方法和组合物
EP3921311A4 (en) * 2019-02-06 2022-11-09 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
KR20210151823A (ko) * 2019-03-15 2021-12-14 스카이호크 테라퓨틱스, 인코포레이티드 비정상적인 스플라이싱을 보정하기 위한 조성물 및 방법
CA3139821A1 (en) * 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
US20220307053A1 (en) 2019-07-25 2022-09-29 Novartis Ag Regulatable expression systems
TW202131920A (zh) 2019-11-01 2021-09-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
AU2021228285A1 (en) 2020-02-28 2022-09-29 Remix Therapeutics Inc. Compounds and methods for modulating splicing
JP2023515620A (ja) 2020-02-28 2023-04-13 リミックス セラピューティクス インコーポレイテッド スプライシングを調節するための化合物及び方法
AU2021228770A1 (en) 2020-02-28 2022-09-29 Remix Therapeutics Inc. Thiophenyl derivatives useful for modulating nucleic acid splicing
IL295953A (en) 2020-02-28 2022-10-01 Remix Therapeutics Inc Pyridazine derivatives regulate nucleic acid splicing
CR20220566A (es) 2020-04-08 2023-01-23 Remix Therapeutics Inc Compuestos y métodos para modular el corte y empalme
JP2023520924A (ja) 2020-04-08 2023-05-22 リミックス セラピューティクス インコーポレイテッド スプライシングを調節するための化合物及び方法
AU2021254418A1 (en) * 2020-04-09 2022-11-03 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
TW202208627A (zh) 2020-05-11 2022-03-01 美商斯托克治療公司 用於病症及疾病之治療的opa1反義寡聚物
EP4149937A1 (en) 2020-05-13 2023-03-22 CHDI Foundation, Inc. Htt modulators for treating huntington's disease
TW202216671A (zh) 2020-06-25 2022-05-01 瑞士商諾華公司 １，４—二取代的嗒𠯤化合物之製造方法
EP4178963A1 (en) 2020-07-02 2023-05-17 Remix Therapeutics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
AU2021299515A1 (en) 2020-07-02 2023-02-02 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
TW202304446A (zh) 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
WO2023034833A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034827A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034836A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
MX2024002558A (es) 2021-08-30 2024-04-30 Remix Therapeutics Inc Compuestos y métodos para modular splicing.
EP4395891A1 (en) 2021-08-30 2024-07-10 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US20240366612A1 (en) 2021-10-13 2024-11-07 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
WO2023064880A1 (en) 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
KR20240115832A (ko) 2021-11-17 2024-07-26 씨에이치디아이 파운데이션, 인코포레이티드 헌팅턴병을 치료하기 위한 htt 조절제
AU2022389987A1 (en) * 2021-11-22 2024-06-06 Rgenta Therapeutics, Inc. Heterocyclic substituted 1,3,4-thiadiazole and pyridazine compounds and methods of using the same
WO2023133229A2 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023133225A1 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023133217A1 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
CN118159524B (zh) * 2022-01-28 2024-12-17 和记黄埔医药（上海）有限公司 咪唑并[1,2-b]哒嗪类化合物的中间体的合成方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2427943C2 (de) 1974-06-10 1984-08-02 Dr. Karl Thomae Gmbh, 7950 Biberach Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2516040C2 (de) 1974-06-10 1984-12-20 Dr. Karl Thomae Gmbh, 7950 Biberach Benzimidazole, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
EP0730590B1 (en) 1993-11-24 2001-01-17 Dupont Pharmaceuticals Company isoxazoline and isoxazole fibrinogen receptor antagonists
AP2002002596A0 (en) 2000-02-11 2002-09-30 Vertex Pharma Piperazine and piperidine derivatives.
EP1133993A1 (en) 2000-03-10 2001-09-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Substances for the treatment of spinal muscular atrophy
EP1289993B9 (en) 2000-06-07 2008-08-20 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
US6376508B1 (en) 2000-12-13 2002-04-23 Academia Sinica Treatments for spinal muscular atrophy
US6982259B2 (en) 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
AU2003264018A1 (en) 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
NZ538339A (en) 2002-08-09 2007-01-26 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
AU2003259068B2 (en) 2002-08-09 2009-07-02 Astrazeneca Ab "1,2,4"oxadiazoles as modulators of metabotropic glutamate receptor-5
JP2006508109A (ja) * 2002-11-11 2006-03-09 ニューロサーチ、アクティーゼルスカブ １，４−ジアザビシクロ（３，２，２）ノナン誘導体、その製造方法及びその使用
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
EP1642898B1 (en) 2003-06-27 2013-03-27 Msd K.K. Heteroaryloxy nitrogenous saturated heterocyclic derivative
CN1835756A (zh) 2003-08-15 2006-09-20 默克公司 有丝分裂驱动蛋白抑制剂
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US7655657B2 (en) * 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
FR2868780B1 (fr) 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
AU2005257859A1 (en) 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
CA2571360C (en) 2004-06-18 2014-11-25 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines useful in inducing cytokine biosynthesis in animals
EP1814551A2 (en) 2004-09-20 2007-08-08 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
PL1637141T3 (pl) 2004-09-21 2012-04-30 Trobio Ab Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej
EP1809282B1 (en) 2004-10-18 2013-01-09 Amgen, Inc Thiadiazole compounds and methods of use
CA2584838A1 (en) * 2004-10-20 2006-05-04 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
ES2375929T3 (es) 2005-07-04 2012-03-07 High Point Pharmaceuticals, Llc Antagonistas del receptor histamina h3.
CN101305004B (zh) * 2005-12-06 2011-11-16 神经研究公司 新颖的二氮杂双环芳基衍生物和它们的医药用途
TW200813051A (en) 2006-05-08 2008-03-16 Neurogen Corp Substituted azaspiro derivatives
US20080247964A1 (en) 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
KR20090018972A (ko) * 2006-05-19 2009-02-24 아보트 러보러터리즈 Ｃｎｓ 활성 융합된 비사이클로헤테로사이클 치환된 아자비사이클릭 알칸 유도체
US20080139598A1 (en) 2006-11-07 2008-06-12 Joseph Barbosa Amine-linked Multicyclic Compounds and Methods of Their Use
GB0704394D0 (en) 2007-03-07 2007-04-11 Senexis Ltd Compounds
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
ES2552733T3 (es) 2007-11-16 2015-12-01 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
NZ736561A (en) 2008-02-28 2018-02-23 Vertex Pharma Heteroaryl derivatives as cftr modulators
WO2009137503A1 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Hdac inhibitors and uses thereof
US20110142758A1 (en) 2008-06-10 2011-06-16 Neurosearch A/S Indolyl-pyridazinyl-diazabicyclononane derivatives in labelled and unlabelled form and their use in diagnostic methods
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
AU2009271414A1 (en) 2008-06-20 2010-01-21 Metabolex, Inc. Aryl GPR119 agonists and uses thereof
AU2009289649B2 (en) 2008-09-03 2016-05-05 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
CA2739491A1 (en) 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
TW201120041A (en) 2009-09-10 2011-06-16 Hoffmann La Roche Inhibitors of JAK
TWI558398B (zh) * 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
MX2012005827A (es) 2009-11-18 2012-06-19 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
US20130096160A1 (en) 2010-04-14 2013-04-18 Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
EP2606022A2 (en) 2010-08-16 2013-06-26 Santhera Pharmaceuticals (Schweiz) AG Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
US20140228398A1 (en) 2011-03-18 2014-08-14 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
UA113223C2 (xx) 2012-08-13 2016-12-26 Арилетинілпіримідини
CA2888338C (en) 2012-11-27 2021-07-20 Thomas Helledays Stiftelse For Medicinsk Forskning Mth1 inhibitors for treatment of cancer
US9040712B2 (en) * 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
US20160184305A1 (en) 2013-07-31 2016-06-30 Novartis Ag 1,4-disubstituted pyridazine quinolne analogs there of and methods for treating smn-deficiency-related conditions

Also Published As

Publication number Publication date
IL237067B (en) 2019-03-31
MY176488A (en) 2020-08-12
AU2013302859B2 (en) 2016-07-14
SG11201500507UA (en) 2015-03-30
UA114726C2 (uk) 2017-07-25
AR092108A1 (es) 2015-03-25
BR112015003004B1 (pt) 2020-09-24
CN104583196B (zh) 2016-10-12
GT201500030A (es) 2017-09-28
JP2015524842A (ja) 2015-08-27
US20170290828A1 (en) 2017-10-12
AU2013302859A1 (en) 2015-02-19
EA032005B1 (ru) 2019-03-29
US20190358226A1 (en) 2019-11-28
PT2885288T (pt) 2022-01-06
KR20200126016A (ko) 2020-11-05
PE20151890A1 (es) 2016-01-13
HK1207862A1 (en) 2016-02-12
WO2014028459A1 (en) 2014-02-20
LT2885288T (lt) 2021-12-27
AP2015008242A0 (en) 2015-01-31
ES2902198T3 (es) 2022-03-25
NZ704738A (en) 2016-02-26
CR20150078A (es) 2015-05-29
SG10201701123QA (en) 2017-04-27
RS62692B1 (sr) 2022-01-31
HUE057007T2 (hu) 2022-04-28
MY174339A (en) 2020-04-09
MX2015001892A (es) 2015-05-07
US20200345732A1 (en) 2020-11-05
CN104583196A (zh) 2015-04-29
CA2880273A1 (en) 2014-02-20
EP4101849A1 (en) 2022-12-14
KR20220029764A (ko) 2022-03-08
KR20150041655A (ko) 2015-04-16
JP6190883B2 (ja) 2017-08-30
ZA201500531B (en) 2018-11-28
MA37834A1 (fr) 2018-09-28
ES2950450T3 (es) 2023-10-10
EA201590371A1 (ru) 2015-06-30
KR102368439B1 (ko) 2022-02-28
CY1124882T1 (el) 2022-11-25
EP2885288B1 (en) 2021-10-06
CU20150014A7 (es) 2015-07-30
EP2885288A1 (en) 2015-06-24
MX2020010151A (es) 2021-01-15
TW201412721A (zh) 2014-04-01
TN2015000038A1 (en) 2016-06-29
CL2015000331A1 (es) 2015-08-28
PE20201165A1 (es) 2020-10-28
EP3564233B1 (en) 2023-05-03
TWI635083B (zh) 2018-09-11
US9545404B2 (en) 2017-01-17
US20140213570A1 (en) 2014-07-31
BR112015003004A2 (pt) 2017-07-04
ECSP15009862A (es) 2019-03-29
US20140051672A1 (en) 2014-02-20
US10758533B2 (en) 2020-09-01
HRP20211957T1 (hr) 2022-03-18
PL2885288T3 (pl) 2022-02-07
US8729263B2 (en) 2014-05-20
DK2885288T3 (da) 2022-01-10
KR102172911B1 (ko) 2020-11-03
US11229648B2 (en) 2022-01-25
MX375731B (es) 2025-03-06
US10195196B2 (en) 2019-02-05
JO3530B1 (ar) 2020-07-05
PH12015500236B1 (en) 2016-02-03
EP3564233A1 (en) 2019-11-06
PH12015500236A1 (en) 2015-03-30
US20220387428A1 (en) 2022-12-08
UY34974A (es) 2014-03-31

Similar Documents

Publication Publication Date Title
IL237067B (en) Disubstituted pyridazine analogs at the 4,1 positions and methods for treating conditions associated with smn deficiency
PL3027600T3 (pl) 1,4-dwupodstawione pochodne pirydazyny i ich zastosowanie do leczenia stanów związanych z niedoborem smn
EP2872641A4 (en) BIOREFINING SYSTEM, METHODS AND COMPOSITIONS THEREOF
IL238416A0 (en) Preparations and methods for the treatment of diseases caused by protein pathology
PT2830662T (pt) Métodos para tratamento de distúrbios de perda de pelo
IL237068A (en) 1,3-dioxanomorphides and 1,3-dioxanocodides
ZA201501752B (en) Methods for treating hepatitis c
IL245805A0 (en) Process for purifying 5,2-dichlorophenol
ZA201501758B (en) Methods for treating hepatitis c
HUE041320T2 (hu) 1,3-Specifikus intraészterezés
GB201201062D0 (en) Radiofluorination method
EP2889039A4 (en) PREPARATION FOR THE PREVENTION OR TREATMENT OF TYPE 1 DIABETES
HRP20200204T1 (hr) Uređaj za elektrolizu i postupak za upravljanje istim
IL238331A0 (en) A method for treating type I and type II diabetes
ZA201404986B (en) Methods for preventing, treating or diagnosing disorders
PL2768527T3 (pl) Wieloważna szczepionka przeciw CBV do zapobiegania lub leczenia cukrzycy typu 1
IL229669A0 (en) Process for the preparation of 1,2,3 triazole 4 carboxamide
EP2938703A4 (en) METHODS AND SYSTEMS FOR IMPROVING COKE EXTINCTION
GB201214387D0 (en) Methods for treating plants
GB201212604D0 (en) New treatment
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载